Unlock instant, AI-driven research and patent intelligence for your innovation.

Medical composition of recombinant Wautersiella asparaginase and preparation method and application thereof

A technology of asparaginase and Worella, applied in the field of biomedicine, can solve the problem of not directly elucidating the anti-cancer activity, etc., and achieve the effect of high-level expression

Inactive Publication Date: 2012-09-12
范铭琦
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Chinese patent [Application No.: 2011062300382900] describes a preparation method of asparaginase from recombinant Wormella bacterium, but the expression level, the use of IPTG (which has certain liver toxicity to humans) as the expression inducer and the penicillin used in the plasmid ( Specific populations have allergic reactions) resistance can not fully meet the preparation requirements as a biological drug, and its anticancer activity has not been directly elucidated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical composition of recombinant Wautersiella asparaginase and preparation method and application thereof
  • Medical composition of recombinant Wautersiella asparaginase and preparation method and application thereof
  • Medical composition of recombinant Wautersiella asparaginase and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Expression of Recombinant Wormella Asparaginase

[0026] Plasmid (pJET / WAP) containing a 1kb DNA fragment of Asparaginase from Wormella spp., digested with Nde I and Sal I (37°C, 1hr), cut out a 1kb DNA fragment, and purified the target DNA with a DNA agarose recovery kit fragment. The purified DNA fragment was inserted between the corresponding Nde I and Sal I of the expression plasmid pET30a, and ligated with T4 DNA ligase. The ligation product was transformed into Escherichia coli BL21 (DE3). Spread on LB+Agar medium containing 30 μg / ml kanamycin; culture at 37°C for 12 hours until a single colony appears, pick the transformant, and place in LB medium containing 30 μg / ml kanamycin Cultivate at 37°C for 4 hours; then in 3L expression medium (peptone 12g / L; yeast extract 24g / L; KH 2 PO 4 0.17mol / L; K 2 HPO 4 0.72mol / L; glycerol 4ml / L; glucose 0.05% (w / v); lactose 0.2% (w / v); magnesium sulfate 2mmol / L; 30μg / ml kanamycin) for 16-18hr. Centrifuge at 6,000g for 20m...

Embodiment 2

[0028] Purification of Recombinant Asparaginase from Wormella

[0029] Take the bacterium suspension described in the above example 3, break it with an ultrasonic cell disruptor, centrifuge again, take the supernatant and put it on a chromatographic column filled with 1.2L of DEAE agarose resin, and use 50mM Tris , pH 7.5, 50 mM NaCl buffer to elute asparaginase. The eluate containing asparaginase was collected and concentrated by ultrafiltration. The concentrate was further purified by 125ml Phenyl Sepharose hydrophobic column chromatography, gradient elution was carried out with phosphate buffer containing 1M ammonium sulfate to 0M ammonium sulfate, and the components containing asparaginase were collected, concentrated by ultrafiltration, The concentrate was dialyzed and the final recombinant asparaginase was stored in 0.1M phosphate buffer (pH 8.0). Use the Bradford method to measure the protein concentration, use the Nestle method to measure the enzyme activity, and use...

Embodiment 3

[0031] Preparation of Recombinant Wormella Asparaginase for Injection

[0032] Take 10,000 units per bottle of the recombinant Wormella asparaginase prepared in Example 2, add 80 mg of mannitol, filter aseptically with a 0.22 μm filter membrane, add to a sterile vial, freeze-dry, and obtain injection Recombinant Asparaginase was used.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to the field of biological medicine, in particular to a medical composition of recombinant Wautersiella asparaginase for treatment of cancer and a preparation method thereof, the medical composition mainly comprises the following ingredients of: 5,000I.U. or 10,000I.U. of recombinant Wautersiella asparaginase respectively containing 40mg or 80mg of mannitol; or 5,000I.U. or 10,000I.U. of recombinant Wautersiella asparaginase respectively containing 24.3mg or 48.6mg of glycocoll, the pH value is 7.0; or 5,000I.U. / 10,000I.U. of recombinant Wautersiella asparaginase, 5mmol / L of L-cysteine, 20mmol / L of phosphoric acid buffer solution, and 0.7 percent of sodium chloride. Genes containing Wautersiella asparaginase are cloned to the express plasmid, and the express plasmid is transfected to the escherichia coli containing gene DE3. The addition of toxic IPTG is avoided during the preparation process of the medical composition of recombinant Wautersiella asparaginase, meanwhile a high-level expression is realized, and the expression plasmid of kanamycin resistance gene can meet the requirement on biological medicine preparation.

Description

[technical field] [0001] The invention relates to the field of biomedicine, in particular to a pharmaceutical composition of recombinant Wormella asparaginase that can be used for treating cancer and a preparation method thereof. [Background technique] [0002] Asparaginase can selectively inhibit the growth of cancer cells, and it is mainly used clinically to treat cancer diseases such as acute lymphocytic leukemia (Acute lymphocytic leukemia) and malignant lymphoma. Most of the currently clinically used products are asparaginases from Escherichia coli (E.coli) and Erwinia (Erwinia carotovora); in 2011, the US FDA also approved another asparaginase from Erwinia chrysanthemi Amidase is used clinically. In addition, the asparaginase of Escherichia coli can also be modified into pegaspargase with polyethylene glycol (Polyethylene Glycol, PEG) to increase its stability and reduce its allergenicity. Its representative products are (Enzon Pharmaceuticals Inc), imitated by Hen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/50C12N9/82A61P35/00
Inventor 范铭琦
Owner 范铭琦